2016 Progress and Controversies in Gynecologic Oncology Conference

Meeting Overview

We are pleased to invite you to the 2016 Progress and Controversies in Gynecologic Oncology Conference, to be held in Barcelona, Spain, on 22-23 January 2016.

This meeting will serve as a valuable forum for the presentation and discussion of newly available data across various gynecologic malignancies, including ovarian, cervical, and endometrial cancers. Participants will be provided with updates on practice-changing data in a practical and interactive format, fostering discussion, and impacting clinical outcomes for patients.

We look forward to welcoming you to the conference.

Sincerely,

Andreas du Bois, MD, PhD
Chair
Stanley B. Kaye, MD
Chair
Ignace Vergote, MD, PhD
Chair

Meeting Chairs
  • Andreas du Bois, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Stanley B. Kaye, MDThe Royal Marsden Hospital
    Sutton, United Kingdom
  • Ignace Vergote, MD, PhDUniversity Hospitals Leuven
    Leuven, European Union
Scientific Committee
  • Nicoletta Colombo, MDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Andrés Poveda, MDFundación Instituto Valenciano de Oncología
    Valencia, Spain
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at
    St. Joseph's Hospital
    Phoenix, Arizona, United States
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France

Target Audience

The 2016 Progress and Controversies in Gynecologic Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners, including allied health professionals involved in the diagnosis and management of gynecologic malignancies.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Develop a practical approach to cervical cancer and vulvar cancer disease management
  • Describe the role of various therapeutic modalities in the management of endometrial cancer
  • Derive the optimal management of ovarian cancer based on disease stage and clinical presentation
  • Assess standard and emerging therapeutic options for recurrent ovarian cancer and discuss their impact on patient outcomes
  • Discuss contemporary strategies for the management of various rare gynecologic malignancies

Continuing Education

2016 Progress and Controversies in Gynecologic Malignancies Conference is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. 2016 Progress and Controversies in Gynecologic Malignancies Conference is designated for a maximum of 9 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

2016 Progress and Controversies in Gynecologic Malignancies Conference has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 9 category 1 (external) CPD credits.

Meeting Chairs

Andreas du Bois, MD, PhD
Kliniken Essen-Mitte
Essen, Germany
Stanley B. Kaye, MD
The Royal Marsden Hospital
Sutton, United Kingdom
Ignace Vergote, MD, PhD
University Hospitals Leuven
Leuven, European Union

Scientific Committee

Nicoletta Colombo, MD
University of Milan-Bicocca
Milan, Italy
Andrés Poveda, MD
Fundación Instituto Valenciano de Oncología
Valencia, Spain
Bradley J. Monk, MD, FACS, FACOG
Creighton University School of Medicine
at St Joseph’s Hospital and Medical Center
Phoenix, Arizona, United States
Eric Pujade-Lauraine, MD, PhD
Centre Hospitalier Universitaire Hôtel-Dieu
Paris, France

Faculty*

Giovanni Aletti, MD
European Institute of Oncology
Milan, Italy
Philipp Harter, MD
Kliniken Essen-Mitte
Essen, Germany
Marcos Ballester, MD, PhD
Tenon Hospital
Paris, France
Sven Mahner, MD, PhD
Klinikum der Universität München
Munich, Germany
Judith Balmaña, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain
Jacobus Pfisterer, MD, PhD
Gynecologic Oncology Center
Kiel, Germany
Luis Chiva, MD, PhD
MD Anderson Cancer Center Madrid
Madrid, Spain
Richard Pӧtter, MD
Medical University of Vienna
Vienna, Austria
An Coosemans, MD, PhD
University Hospitals Leuven
Leuven, Belgium
Nicholas Reed, MD
Beatson Oncology Centre
Gartnavel General Hospital
Glasgow, Scotland
Antonio González Martín, MD
MD Anderson Cancer Center Madrid
Madrid, Spain
Michael Seckl, MD, PhD
Imperial College
London, United Kingdom

Agenda

Friday, 22 January 2016

13.00 Welcome and introduction

Session I Cervical Cancer and Vulvar Cancer

13.10 Debate
Neoadjuvant chemotherapy versus primary radiochemotherapy in FIGO IB2 cervical cancer
Neoadjuvant chemotherapy: Giovanni Aletti, MD
Primary radiochemotherapy: Richard Pӧtter, MD
13.50 Reconstructive surgery for vulvar cancer
Sven Mahner, MD, PhD
14.20 Targeted therapy for cervical cancer
Bradley J. Monk, MD, FACS, FACOG
14.50 Break

Session II Endometrial Cancer

15.20 Sentinel node biopsy in endometrial cancer: Ready for prime time?
Marcos Ballester, MD, PhD
15.50 Systemic treatment of endometrial cancer: Are there any new agents in sight?
Andrés Poveda, MD
16.20 How to incorporate clinical trials into routine daily clinical practice
Jacobus Pfisterer, MD, PhD
Special Session—Hot Topics in Gynecologic Oncology

16.50 Background of immunologic therapy in gynecologic cancer
An Coosemans, MD, PhD
17.20 Day 1 concluding remarks and adjourn

Saturday, 23 January 2016

08.30 Welcome and introduction

Session III Ovarian Neoplasm I: Recurrence

08.35 State of the art: Platinum-resistant disease
Ignace Vergote, MD, PhD
09.05 State of the art: Platinum-sensitive disease
Andreas du Bois, MD, PhD
09.35 Strategies for patients with ovarian cancer who have received multiple prior therapies
Eric Pujade-Lauraine, MD, PhD
10.05 Break

Session IV Ovarian Neoplasm II: Emerging Concepts

10.35 News from the 5th Ovarian Cancer Consensus Conference: Consequences for clinical practice?
Antonio González Martín, MD
11.05 Genetic testing for ovarian cancer: When, how, and who?
Judith Balmaña, MD, PhD
11.35 DNA repair inhibitors as targeted agents: Current status and future strategies
Stanley B. Kaye, MD
12.05 Break
12.30 Industry-supported satellite symposium
13.50 Break

Session V Ovarian Neoplasm III: Practical Issues

14.05 Residual tumor following surgery: The strongest prognostic factor or a myth?
Philipp Harter, MD
14.35 Thoracic surgery in ovarian cancer: Why, when, and how?
Luis Chiva, MD, PhD

Session VI Rare Tumors: State of the Art

15.05 Sex cord tumors
Nicoletta Colombo, MD
15.35 Gestational trophoblastic neoplasia
Michael Seckl, MD, PhD
16.05 Uterine sarcoma
Nicholas Reed, MD
16.35 Day 2 concluding remarks
16.45 Adjourn

Registration

REGISTRATION FEES

Early Regular Late
Physician € 375,- € 475,- € 575,-
Nurse € 225,- € 300,- € 350,-
Fellow/Resident/Student € 225,- € 300,- € 350,-
Industry € 425,- € 525,- € 625,-

Registration fees include VAT.
*Support documentation of eligibility may be required.

Your registration fee will include:

  • Access to all sessions and exhibition
  • Lunch and coffee breaks
  • Congress documentation

Registration Deadlines
Early registration rate: 1 November 2015 (23.59 CET)
Regular registration rate: 29 November 2015 (23.59 CET)

To Register:
You may register online through 20 January 2016 at www.prIMEoncology.org/gynconference2016. Registration confirmations will be issued upon successful completion of registration and reminders will be issued before the meeting. To preregister, registration and payment must be received no later than 1 November 2015 (early registration rate) or 30 November 2015 (regular registration rate). Please register onsite after 20 January 2016.

Group Registrations
Group registrations will be accepted.
For more information, please contact: registrations.gyn2016@prIMEoncology.org.

Terms of Payment
All payments must be made in Euros. Payments can be made by credit card.

Registration will only be valid upon receipt of full payment by prIME Oncology. Outstanding payment must be settled onsite by credit card.


Cancellation

To receive a refund of registration fees, written notice of cancellation must be received at registrations.gyn2016@prIMEoncology.org.

The following deadlines and cancellation fee schedule will apply:

  • Before 1 November 2015: € 50,- administrative charge
  • From 1 November 2015: 60% cancellation fee applies on registration fee(s)
  • From 30 November 2015: 100% cancellation fee applies on registration fee(s)
  • Name changes from 30 November 2015: € 15,-fee is charged per change

Any registration fees remitted will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 29 November 2015.

prIME Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Hotel

We are sorry but the hotel accommodation at the Crowne Plaza – Fira Center is sold out.

General Info

CONTACT
All inquiries related to the 2016 Progress and Controversies in Gynecologic Oncology Conference may be addressed to gyncongress2016@prIMEoncology.org.

EU OFFICE
Schenkkade 50, Suite 16
2595 AR The Hague
the Netherlands

Tel.: + 31 70 30 67 190
Fax: + 31 70 33 18 335
Web: www.prIMEoncology.org

ENTRY REQUIREMENTS
Most EU citizens only need their national identity card or passport to enter Spain. Non-EU citizens require a valid passport to enter Spain, but many countries are exempt from tourist visas. It is essential that you check with the Spanish embassy or consulate in your country before travelling. Without exception, passports must be valid for at least six months after your planned date of departure from Spain.

prIME Oncology will not directly contact embassies and consulates on behalf of applicants. It is the sole responsibility of the delegates to look after their visa requirements.

Note: Passport and visa requirements are liable to change at short notice. Travelers are advised to check their entry requirements with their embassy or consulate.

GETTING THERE
From Barcelona’s main International airport ‘El Prat’ you can travel different ways to the Congress venue:

TAXI: Barcelona has 11,500 taxis easily identified by their yellow and black color. It takes 15/20 minutes, depending on traffic.

AEROBUS: This special service is clearly signposted at the stops outside the terminal and it takes you to different parts of the city. The Plaza de España stop is the closest to the hotel, approximately a 5-minute walk from the stop to the hotel.

TRAIN: The station is located to the West of the terminal. Trains go to “Sants” Station. From here you can take either the Metro—2 stops to Plaza de España and then a 10/15-minute walk—or a taxi.

CAR: Take the Castelldefels Motorway (C-31) toward Barcelona up to Plaza de España. Turn right into Avenida Maria Cristina and drive up until you see the National Palace. Turn left into Avenida Rius i Taulet and carry on straight until Lleida Street. The hotel is right on the corner.

LOCAL TRANSPORT
Barcelona has a very good public transport system (TMB), with special ten-trip and one-day, two-day, and three-day tickets available for bus, metro, and local trains. You can call a taxi or flag them down in the streets. In many taxis you can also pay by credit card.

CLIMATE
Barcelona has a Mediterranean climate with mild, sunny winters, warm summers, and relatively low rainfall. In January the average temperatures are at 13° Celsius (55.4° Fahrenheit).

TIME ZONE
Barcelona is in the Central European time zone (GMT +1).

LANGUAGE
Spanish and Catalan are the two main languages spoken in Barcelona. English is also widely spoken and to some extent French and German.

CURRENCY
The Spanish currency is the Euro €.

TAXES
Value-added tax, or VAT, is otherwise known as IVA (impuesto sobre el valor añadido). The IVA is 10% on accommodation and restaurant prices and is usually, but not always, included in quoted prices. On retail goods the IVA is 21%. IVA-free shopping is available in duty-free shops at all airports for people travelling between EU countries.

TIPPING
Tips are already included in restaurant bills, but it is customary to round up an extra 5% to 10% if you are satisfied with the service. Porters are generally tipped € 1,-per bag.

Support

This educational activity is supported by F. Hoffmann-La Roche Ltd. and ImmunoGen, Inc.

Saturday’s satellite symposium is supported by F. Hoffmann-La Roche Ltd.

Several options are available to organizations interested in supporting this conference. For more information, please contact Katie Eustace +31 70 30 67 190, or by email at Katie.Eustace@prIMEoncology.org.

Register Now

Video Message

DYTLTE_Web_Banner_179x127

Printed Materials

Printed Materials

DATE AND LOCATION

Friday, 22 January 2016
Saturday, 23 January 2016

Crowne Plaza Barcelona – Fira Center
Avda Rius I Taulet, 1-3
Barcelona, Spain

Provider

This activity is provided by prIME Oncology.prime_provider